Addf and aftd partner to support wave life sciences' ftd and als clinical program

New york, jan. 25, 2022 /prnewswire/ -- the alzheimer's drug discovery foundation (addf) and the association for frontotemporal degeneration (aftd) announced today that they have partnered to support wave life sciences' focus-c9 phase 1b/2a clinical trial investigating wve-004 as a potential treatment for c9orf72-associated frontotemporal degeneration (c9-ftd), as well as amyotrophic lateral sclerosis (c9-als). the partnership provides an investment from addf and aftd that will support the evaluation of fluid biomarkers, functional assessments, and digital biomarkers in focus-c9, potentially leading to clinically meaningful endpoints to inform development of treatments for ftd.
WVE Ratings Summary
WVE Quant Ranking